Peo in Interest of Baskerville

CourtColorado Court of Appeals
DecidedDecember 4, 2025
Docket25CA1594
StatusUnpublished

This text of Peo in Interest of Baskerville (Peo in Interest of Baskerville) is published on Counsel Stack Legal Research, covering Colorado Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Peo in Interest of Baskerville, (Colo. Ct. App. 2025).

Opinion

25CA1594 Peo in Interest of Baskerville 12-04-2025

COLORADO COURT OF APPEALS

Court of Appeals No. 25CA1594 Pueblo County District Court No. 25MH30077 Honorable Amiel Markenson, Judge

The People of the State of Colorado,

Petitioner-Appellee,

In the Interest of Christon Baskerville,

Respondent-Appellant.

ORDER AFFIRMED

Division VI Opinion by JUDGE WELLING Gomez and Sullivan, JJ., concur

NOT PUBLISHED PURSUANT TO C.A.R. 35(e) Announced December 4, 2025

Cynthia Mitchell, County Attorney, Kate H. Shafer, Special Assistant County Attorney, Pueblo, Colorado, for Petitioner-Appellee

Tezak Law, P.C., Mary Tezak, Florence, Colorado, for Respondent-Appellant ¶1 Respondent, Christon Baskerville, appeals the district court

order authorizing staff at the Colorado Mental Health Hospital in

Pueblo (CMHHIP) to medicate him against his will. We affirm.

I. Background

¶2 Baskerville, also known as Christon X, was admitted to

CMHHIP after being found incompetent to proceed on criminal

charges. According to the affidavit of Dr. Hareesh Pillai,

Baskerville’s treating physician, Baskerville has a history of

psychiatric hospitalizations and suffers from psychosis – not

otherwise specified.

¶3 CMHHIP began administering psychiatric medications to

Baskerville against his will on an emergency basis after he

challenged a peer to a fight, posturing with his fists up and

threatening “I’ll fuck you up.” The People then petitioned for a six-

month order authorizing the continued involuntary administration

of Zyprexa, Depakote, and Thorazine — Zyprexa and Depakote on a

scheduled basis, and Thorazine only as needed for episodes of acute

agitation or refusals of oral Depakote.

¶4 Both Dr. Pillai and Baskerville testified at the evidentiary

hearing. Dr. Pillai testified about each of the four elements required

1 for involuntary administration of medication under People v.

Medina, 705 P.2d 961, 973 (Colo. 1985).1 Dr. Pillai described

Baskerville’s symptoms, his agitated and aggressive behavior

toward his peers in CMHHIP, and the need for an order authorizing

the involuntary administration of both antipsychotic and mood-

stabilizing medications. Baskerville testified that he objected to

taking psychiatric medications because, among other reasons listed

in Part III.B below, he didn’t need them, doing so is against his

religious beliefs, and they cause sedation. He preferred to treat

himself with yoga and dancing.

¶5 At the conclusion of the hearing, the district court found

Dr. Pillai’s testimony to be credible and persuasive. It found that

the People had provided clear and convincing evidence for each of

the Medina elements, and it issued an order authorizing CMHHIP

1 When the state seeks to administer antipsychotic drugs to a

mentally ill criminal defendant involuntarily so that he can stand trial, a reviewing court applies the Supreme Court’s test in Sell v. United States, 539 U.S. 166, 178 (2003). However, reviewing courts apply state law tests if the state, as here, seeks to administer antipsychotics involuntarily for “a different purpose,” including a purpose “related to the individual’s dangerousness, or . . . the individual’s own interests where refusal to take drugs puts his health gravely at risk.” Id. at 181-82.

2 staff to administer all of the requested medications for a period of

six months.

¶6 On appeal, Baskerville challenges the sufficiency of the

evidence supporting the court’s order.

II. Legal Authority and Standard of Review

¶7 A district court may authorize the involuntary administration

of medication to a patient if the treating facility establishes each of

the following Medina elements by clear and convincing evidence:

(1) the patient is incompetent to participate effectively in the

treatment decision; (2) treatment by medication is necessary either

to prevent a significant and likely long-term deterioration in the

patient’s mental condition or to prevent the likelihood of the patient

causing serious harm to himself or others in the institution; (3) a

less intrusive treatment alternative is not available; and (4) the

patient’s need for treatment with medication is sufficiently

compelling to override his bona fide and legitimate interest in

refusing medication. Id.; see People in Interest of Strodtman, 293

P.3d 123, 131 (Colo. App. 2011). A physician’s testimony alone

may constitute clear and convincing evidence. See People v.

Pflugbeil, 834 P.2d 843, 846-47 (Colo. App. 1992).

3 ¶8 When, as here, a patient challenges the sufficiency of the

evidence, we review the record as a whole and, viewing it in the light

most favorable to the People, determine whether the evidence is

sufficient to support the court’s decision. People in Interest of

Ramsey, 2023 COA 95, ¶ 23. We review the court’s conclusions of

law de novo and defer to its findings of fact if supported by evidence

in the record. People v. Marquardt, 2016 CO 4, ¶ 8. We also defer

to the district court’s resolution of evidentiary conflicts and its

determinations of witness credibility, the weight of the evidence,

and the inferences to be drawn from it. See People in Interest of

R.C., 2019 COA 99M, ¶ 7.

III. Analysis

¶9 Baskerville challenges the sufficiency of the evidence for only

the first and fourth Medina elements. He argues that Dr. Pillai’s

testimony didn’t show (1) that he was incapable of effectively

participating in treatment decisions; or (2) a sufficiently compelling

need to override his interests in refusing the requested medications.

See Medina, 705 P.2d at 973-74. We conclude that the record

provides ample support for the court’s findings.

4 A. The First Medina Element

¶ 10 Baskerville argues that the evidence offered by the People falls

short in light of his testimony acknowledging that he has a mental

illness. We disagree.

¶ 11 A patient is incompetent to effectively participate in treatment

decisions when his “mental illness has so impaired his judgment as

to render him ‘incapable of participating in decisions affecting his

health.’” Id. at 973 (citation omitted). Although the first Medina

element may be satisfied if a patient fails to recognize that he has a

mental illness, see People in Interest of C.J.R., 2016 COA 133, ¶ 32,

the converse isn’t necessarily true.

¶ 12 Dr. Pillai testified, and the district court found credible, that

Baskerville lacked insight into his mental illness and that he was

incompetent to effectively participate in his treatment decisions

because his mental illness causes paranoia, delusions, impulsivity,

and agitation.

¶ 13 Baskerville’s testimony provided support for Dr. Pillai’s

opinions. Although Baskerville acknowledged that he suffers from a

mental illness, his inconsistent assessment of his illness — when

first asked, he reported that he suffers from mild schizophrenia,

5 and, on reconsideration a few minutes later, bipolar disorder —

demonstrated a lack of insight. Baskerville further demonstrated

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sell v. United States
539 U.S. 166 (Supreme Court, 2003)
People v. Medina
705 P.2d 961 (Supreme Court of Colorado, 1985)
People v. Pflugbeil
834 P.2d 843 (Colorado Court of Appeals, 1992)
People v. Marquardt
2016 CO 4 (Supreme Court of Colorado, 2016)
People Ex Rel. C.J.R.
2016 COA 133 (Colorado Court of Appeals, 2016)
People ex rel. Strodtman
293 P.3d 123 (Colorado Court of Appeals, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Peo in Interest of Baskerville, Counsel Stack Legal Research, https://law.counselstack.com/opinion/peo-in-interest-of-baskerville-coloctapp-2025.